-
Dual listing on Euronext growth Brussels
ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company is pleased to announce that its shares will be admitted to trading on Euronext Growth Brussels (“Euronext”) under ticker ‘ALIMM’ following the approval by Euronext of its request for listing. Admission is expected to take effect from 19 December 2019. This new listing does not…
-
Share price volatility
ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, announces that following the recently announced licensing and development agreement with Avion, the US speciality pharmaceutical company, in which Avion will fund an international Phase III trial for our lead programme, Lupuzor™, we note the volatility in the Company’s share price and speculation concerning a…
-
ImmuPharma to present at Biotech Showcase™ 2020 in San Francisco
ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, is pleased to announced that it will be presenting at the Biotech Showcase™ 2020, to be held between 13–15 January 2020, at the Hilton, San Francisco Union Square. Dr Tim Franklin, Commercial Advisor to ImmuPharma, will be presenting to conference attendees on 14th January 2020…
-
TR1 – Notification of major interest in shareholdings
TR1 – Notification of major interest in shareholdings Please click here
-
ImmuPharma and Avion Pharmaceuticals sign exclusive licence
ImmuPharma and Avion Pharmaceuticals sign exclusive licence and development agreement and trademark agreement for Lupuzor™ with Avion to fund new international Phase III trial and commercialise in the US ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, announces a licence and development agreement with Avion Pharmaceuticals LLC, for the exclusive rights to Lupuzor™…
-
INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2019
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2019 (the “Period”). Key Highlights (including post Period review) Financials Stable financial performance over the Period – Cash balance of £2.3 million as at 30 June 2019 (31 December…
-
TR1 – Notification of Major Interest – Lanstead Capital Investors
For further information click here
-
2019 Annual General Meeting – All resolutions passed
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed.
-
Primary endpoint successfully met from the open label extension study evaluating safety and tolerability from the Pivotal Phase III trial of Lupuzor™ in patients with Systemic Lupus Erythematosus (“Lupus”)
Study demonstrates robust safety profile of Lupuzor™ with no ‘serious adverse events’ reported ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce analysis of the results from the open label six month extension study from its original Pivotal Phase III trial of Lupuzor™, its lead programme for the potential breakthrough…
